In Situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter

C. Pramudji, S. Shimura, S. Ebara, G. Yang, J. Wang, C. Ren, Y. Yuan, S. A. Tahir, T. L. Timme, T. C. Thompson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Caveolin-1, a structural component of caveolae, is over-expressed in metastatic and androgen-resistant prostate cancer and highly expressed in tumor-associated endothelial cells. The mouse cav-1 promoter was cloned and placed upstream of the HSV-tk gene in an adenoviral vector (Adcav-1tk) and compared with a cytomegalovirus (CMV) or Rous sarcoma virus (RSV) promoter-driven HSV-tk, AdCMVtk and AdRSVtk vectors, respectively. Mouse and human prostate cancer cells and mouse endothelial cells were infected with Adcav-1tk, AdCMVtk or control vectors without the HSV-tk gene (Adcav-1 and AdCMV) and subsequently treated with ganciclovir (GCV). GCV-mediated in vitro cytotoxicity induced by the Adcav-1tk vector was comparable to that for AdCMVtk in multiple mouse and human prostate cancer cell lines. To evaluate the activity of Adcav1tk in vivo, orthotopic mouse prostate cancer tumors were generated with RM-9 cells and injected in situ with Adcav1-tk, AdCMVtk, AdRSVtk, or AdCMVβgal (control) and treated with GCV. All three HSV-tk transducing vectors produced statistically significant reductions in wet weight and increased apoptotic indices compared with the control vector. However, only Adcav-1tk produced significant necrosis, and only Adcav-1tk and AdRSVtk caused significant decreases in microvessel density. In conclusion, Adcav-1tk demonstrated efficacy in vitro and in vivo in preclinical models of prostate cancer. Our results suggest that the cav-1 promoter may have unique benefits in targeting gene therapy to prostate cancer and its associated vasculature.

Original languageEnglish
Pages (from-to)4272-4279
Number of pages8
JournalClinical Cancer Research
Volume7
Issue number12
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Caveolin 1
Neoplasm Genes
Genetic Therapy
Prostatic Neoplasms
Ganciclovir
Endothelial Cells
Rous sarcoma virus
Caveolae
Microvessels
Cytomegalovirus
Androgens
Genes
Neoplasms
Necrosis
Weights and Measures
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pramudji, C., Shimura, S., Ebara, S., Yang, G., Wang, J., Ren, C., ... Thompson, T. C. (2001). In Situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clinical Cancer Research, 7(12), 4272-4279.

In Situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. / Pramudji, C.; Shimura, S.; Ebara, S.; Yang, G.; Wang, J.; Ren, C.; Yuan, Y.; Tahir, S. A.; Timme, T. L.; Thompson, T. C.

In: Clinical Cancer Research, Vol. 7, No. 12, 2001, p. 4272-4279.

Research output: Contribution to journalArticle

Pramudji, C, Shimura, S, Ebara, S, Yang, G, Wang, J, Ren, C, Yuan, Y, Tahir, SA, Timme, TL & Thompson, TC 2001, 'In Situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter', Clinical Cancer Research, vol. 7, no. 12, pp. 4272-4279.
Pramudji C, Shimura S, Ebara S, Yang G, Wang J, Ren C et al. In Situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clinical Cancer Research. 2001;7(12):4272-4279.
Pramudji, C. ; Shimura, S. ; Ebara, S. ; Yang, G. ; Wang, J. ; Ren, C. ; Yuan, Y. ; Tahir, S. A. ; Timme, T. L. ; Thompson, T. C. / In Situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. In: Clinical Cancer Research. 2001 ; Vol. 7, No. 12. pp. 4272-4279.
@article{58d20adce13a4c248c9e9519cf9a726c,
title = "In Situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter",
abstract = "Caveolin-1, a structural component of caveolae, is over-expressed in metastatic and androgen-resistant prostate cancer and highly expressed in tumor-associated endothelial cells. The mouse cav-1 promoter was cloned and placed upstream of the HSV-tk gene in an adenoviral vector (Adcav-1tk) and compared with a cytomegalovirus (CMV) or Rous sarcoma virus (RSV) promoter-driven HSV-tk, AdCMVtk and AdRSVtk vectors, respectively. Mouse and human prostate cancer cells and mouse endothelial cells were infected with Adcav-1tk, AdCMVtk or control vectors without the HSV-tk gene (Adcav-1 and AdCMV) and subsequently treated with ganciclovir (GCV). GCV-mediated in vitro cytotoxicity induced by the Adcav-1tk vector was comparable to that for AdCMVtk in multiple mouse and human prostate cancer cell lines. To evaluate the activity of Adcav1tk in vivo, orthotopic mouse prostate cancer tumors were generated with RM-9 cells and injected in situ with Adcav1-tk, AdCMVtk, AdRSVtk, or AdCMVβgal (control) and treated with GCV. All three HSV-tk transducing vectors produced statistically significant reductions in wet weight and increased apoptotic indices compared with the control vector. However, only Adcav-1tk produced significant necrosis, and only Adcav-1tk and AdRSVtk caused significant decreases in microvessel density. In conclusion, Adcav-1tk demonstrated efficacy in vitro and in vivo in preclinical models of prostate cancer. Our results suggest that the cav-1 promoter may have unique benefits in targeting gene therapy to prostate cancer and its associated vasculature.",
author = "C. Pramudji and S. Shimura and S. Ebara and G. Yang and J. Wang and C. Ren and Y. Yuan and Tahir, {S. A.} and Timme, {T. L.} and Thompson, {T. C.}",
year = "2001",
language = "English",
volume = "7",
pages = "4272--4279",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - In Situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter

AU - Pramudji, C.

AU - Shimura, S.

AU - Ebara, S.

AU - Yang, G.

AU - Wang, J.

AU - Ren, C.

AU - Yuan, Y.

AU - Tahir, S. A.

AU - Timme, T. L.

AU - Thompson, T. C.

PY - 2001

Y1 - 2001

N2 - Caveolin-1, a structural component of caveolae, is over-expressed in metastatic and androgen-resistant prostate cancer and highly expressed in tumor-associated endothelial cells. The mouse cav-1 promoter was cloned and placed upstream of the HSV-tk gene in an adenoviral vector (Adcav-1tk) and compared with a cytomegalovirus (CMV) or Rous sarcoma virus (RSV) promoter-driven HSV-tk, AdCMVtk and AdRSVtk vectors, respectively. Mouse and human prostate cancer cells and mouse endothelial cells were infected with Adcav-1tk, AdCMVtk or control vectors without the HSV-tk gene (Adcav-1 and AdCMV) and subsequently treated with ganciclovir (GCV). GCV-mediated in vitro cytotoxicity induced by the Adcav-1tk vector was comparable to that for AdCMVtk in multiple mouse and human prostate cancer cell lines. To evaluate the activity of Adcav1tk in vivo, orthotopic mouse prostate cancer tumors were generated with RM-9 cells and injected in situ with Adcav1-tk, AdCMVtk, AdRSVtk, or AdCMVβgal (control) and treated with GCV. All three HSV-tk transducing vectors produced statistically significant reductions in wet weight and increased apoptotic indices compared with the control vector. However, only Adcav-1tk produced significant necrosis, and only Adcav-1tk and AdRSVtk caused significant decreases in microvessel density. In conclusion, Adcav-1tk demonstrated efficacy in vitro and in vivo in preclinical models of prostate cancer. Our results suggest that the cav-1 promoter may have unique benefits in targeting gene therapy to prostate cancer and its associated vasculature.

AB - Caveolin-1, a structural component of caveolae, is over-expressed in metastatic and androgen-resistant prostate cancer and highly expressed in tumor-associated endothelial cells. The mouse cav-1 promoter was cloned and placed upstream of the HSV-tk gene in an adenoviral vector (Adcav-1tk) and compared with a cytomegalovirus (CMV) or Rous sarcoma virus (RSV) promoter-driven HSV-tk, AdCMVtk and AdRSVtk vectors, respectively. Mouse and human prostate cancer cells and mouse endothelial cells were infected with Adcav-1tk, AdCMVtk or control vectors without the HSV-tk gene (Adcav-1 and AdCMV) and subsequently treated with ganciclovir (GCV). GCV-mediated in vitro cytotoxicity induced by the Adcav-1tk vector was comparable to that for AdCMVtk in multiple mouse and human prostate cancer cell lines. To evaluate the activity of Adcav1tk in vivo, orthotopic mouse prostate cancer tumors were generated with RM-9 cells and injected in situ with Adcav1-tk, AdCMVtk, AdRSVtk, or AdCMVβgal (control) and treated with GCV. All three HSV-tk transducing vectors produced statistically significant reductions in wet weight and increased apoptotic indices compared with the control vector. However, only Adcav-1tk produced significant necrosis, and only Adcav-1tk and AdRSVtk caused significant decreases in microvessel density. In conclusion, Adcav-1tk demonstrated efficacy in vitro and in vivo in preclinical models of prostate cancer. Our results suggest that the cav-1 promoter may have unique benefits in targeting gene therapy to prostate cancer and its associated vasculature.

UR - http://www.scopus.com/inward/record.url?scp=0035675839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035675839&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 4272

EP - 4279

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -